ACSS2 and fatty liver disease: Recent studies have shown that inhibiting SREBP1, ACLY, ACSS2, ACACA, and FASN can improve fatty liver disease (Knebel et al., 2018; Morrow et al., 2022; Huang et al., 2018; Chen et al., 2019; Loomba et al., 2021).